Multiple myeloma

被引：674

作者：

Raab, Marc S. ^{[1
,2
,3
,4
,5
]}

Podar, Klaus ^{[1
,2
]}

Breitkreutz, Iris ^{[1
,2
,4
,5
]}

Richardson, Paul G. ^{[1
,2
]}

Anderson, Kenneth C. ^{[1
,2
]}

机构：

[1] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA

[3] Heidelberg Univ, Med Ctr, Dept Med 5, Heidelberg, Germany

[4] Natl Ctr Tumor Dis, Heidelberg, Germany

[5] German Canc Res Ctr, D-6900 Heidelberg, Germany

来源：

LANCET | 2009年 / 374卷 / 9686期

关键词：

STEM-CELL TRANSPLANTATION; THALIDOMIDE PLUS DEXAMETHASONE; HIGH-DOSE THERAPY; PEGYLATED LIPOSOMAL DOXORUBICIN; PROTEASOME INHIBITOR BORTEZOMIB; BONE-MARROW-TRANSPLANTATION; PREVIOUSLY TREATED PATIENTS; MONOCLONAL GAMMOPATHY; HIGH-RISK; ELDERLY-PATIENTS;

D O I：

10.1016/S0140-6736(09)60221-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Multiple myeloma is characterised by clonal proliferation of malignant plasma cells, and mounting evidence indicates that the bone marrow microenvironment of tumour cells has a pivotal role in myeloma pathogenesis. This knowledge has already expanded treatment options for patients with multiple myeloma. Prototypic drugs thalidomide, bortezomib, and lenalidomide have each been approved for the treatment of this disease by targeting both multiple myeloma cells and the bone marrow microenvironment. Although benefit was first shown in relapsed and refractory disease, improved overall response, duration of response, and progression-free and overall survival can be achieved when these drugs are part of first-line regimens. This treatment framework promises to improve outcome not only for patients with multiple myeloma, but also with other haematological malignancies and solid tumours.

引用

页码：324 / 339

页数：16

共 150 条

[1] EARLY MYELOABLATIVE THERAPY FOR MULTIPLE-MYELOMA [J].

ALEXANIAN, R ;

DIMOPOULOS, MA ;

HESTER, J ;

DELASALLE, K ;

CHAMPLIN, R .

BLOOD, 1994, 84 (12) :4278-4282

[2]

ALEXANIAN R, 1986, ANN INTERN MED, V105, P8, DOI 10.7326/0003-4819-105-1-8

[3]

Anderson KC, 1999, SEMIN HEMATOL, V36, P3

[4] Lenalidomide and thalidomide: Mechanisms of action - Similarities and differences [J].

Anderson, KC .

SEMINARS IN HEMATOLOGY, 2005, 42 (04) :S3-S8

[5]

ANDERSON KC, 2008, P AN M AM SOC CLIN, V26, P8545

[6] Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma [J].

Arnulf, B. ;

Lecourt, S. ;

Soulier, J. ;

Ternaux, B. ;

Lacassagne, M-Noelle ;

Crinquette, A. ;

Dessoly, J. ;

Sciaini, A-K ;

Benbunan, M. ;

Chomienne, C. ;

Fermand, J-P ;

Marolleau, J-P ;

Larghero, J. .

LEUKEMIA, 2007, 21 (01) :158-163

[7] Single versus double autologous stem-cell transplantation for multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Facon, T ;

Guilhot, F ;

Doyen, C ;

Fuzibet, JG ;

Monconduit, M ;

Hulin, C ;

Caillot, D ;

Bouabdallah, R ;

Voillat, L ;

Sotto, JJ ;

Grosbois, B ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (26) :2495-2502

[8] A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Stoppa, AM ;

Sotto, JJ ;

Fuzibet, JG ;

Rossi, JF ;

Casassus, P ;

Maisonneuve, H ;

Facon, T ;

Ifrah, N ;

Payen, C ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97

[9] Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma [J].

Attal, Michel ;

Harousseau, Jean-Luc ;

Leyvraz, Serge ;

Doyen, Chantal ;

Hulin, Cyrille ;

Benboubker, Lofti ;

Agha, Ibrahim Yakoub ;

Bourhis, Jean-Henri ;

Garderet, Laurent ;

Pegourie, Brigitte ;

Dumontet, Charles ;

Renaud, Marc ;

Voillat, Laurent ;

Berthou, Christian ;

Marit, Gerald ;

Monconduit, Mathieu ;

Caillot, Denis ;

Grobois, Bernard ;

Avet-Loiseau, Herve ;

Moreau, Philippe ;

Facon, Thierry .

BLOOD, 2006, 108 (10) :3289-3294

[10]

Avet-Loiseau H, 1999, CANCER RES, V59, P4546

← 1 2 3 4 5 6 7 8 9 10 →